Inventor · disambiguated record
Chengde Wu
Also filed as: WU CHENGDE
60 granted patents·22 pending applications·1,409 citations·filing 1993–2022
99Inventor score
Files withTEXAS BIOTECHNOLOGY CORP19ENCYSIVE PHARMACEUTICALS INC9MEDSHINE DISCOVERY INC9GLAXOSMITHKLINE IP DEV LTD5CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD4
Top patents by PatentIndex Score
82 records- 0197US5571821ASulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1994·Granted Nov 5, 1996·125 cites·91 claims
- 0296US9035063B2Compounds as rearranged during transfection (RET) inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted May 19, 2015·55 cites·8 claims
- 0395US5594021AThienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1995·Granted Jan 14, 1997·88 cites·174 claims
- 0495US5514691AN-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelinIMMUNOPHARMACEUTICS INC·Filed 1993·Granted May 7, 1996·128 cites·94 claims
- 0595US5464853AN-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelinIMMUNOPHARMACEUTICS INC·Filed 1993·Granted Nov 7, 1995·100 cites·25 claims
- 0694US8937071B2Compounds as rearranged during transfection (RET) inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2014·Granted Jan 20, 2015·59 cites·15 claims
- 0792US5962490AThienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Oct 5, 1999·93 cites·97 claims
- 0890US7320989B2Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonistsENCYSIVE PHARMACEUTICALS INC·Filed 2004·Granted Jan 22, 2008·43 cites·4 claims
- 0989US7265122B2Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonistsENCYSIVE PHARMACEUTICALS INC·Filed 2004·Granted Sep 4, 2007·49 cites·4 claims
- 1088US6458805B2Formulation of sulfonamides for treatment of endothelin-mediated disordersTEXAS BIOTECHNOLOGY CORP·Filed 2001·Granted Oct 1, 2002·30 cites·65 claims
- 1188US5977117ASubstituted phenyl compounds and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Nov 2, 1999·72 cites·73 claims
- 1288US5591761AThiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1994·Granted Jan 7, 1997·67 cites·93 claims
- 1387US11542272B2Five-membered heteroaryl-fused imidazole compound and application thereofHANGZHOU SCIWIND BIOSCIENCES CO LTD·Filed 2022·Granted Jan 3, 2023·2 cites·19 claims
- 1487US6683103B2Sulfonamides for treatment of endothelin-mediated disordersENCYSIVE PHARMACEUTICALS INC·Filed 2001·Granted Jan 27, 2004·26 cites·44 claims
- 1585US7579340B2Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonistsPFIZER·Filed 2007·Granted Aug 25, 2009·4 cites·6 claims
- 1685US6723711B2Propanoic acid derivatives that inhibit the binding of integrins to their receptorsTEXAS BIOTECHNOLOGY CORP·Filed 2001·Granted Apr 20, 2004·35 cites·13 claims
- 1782US5783705AProcess of preparing alkali metal salys of hydrophobic sulfonamidesTEXAS BIOTECHNOLOGY CORP·Filed 1997·Granted Jul 21, 1998·48 cites·11 claims
- 1881US11332465B2Diarylthiohydantoin compound as androgen receptor antagonistCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2018·Granted May 17, 2022·3 cites·20 claims
- 1981US6541498B2Benzenesulfonamides and the use thereof to modulate the activity of endothelinTEXAS BIOTECHNOLOGY·Filed 2000·Granted Apr 1, 2003·15 cites·43 claims
- 2081US6248767B1Formulation of sulfonamides for treatment of endothelin-mediated disordersTEXAS BIOTECHNOLOGY CORP·Filed 1997·Granted Jun 19, 2001·46 cites·66 claims
- 2181US6194448B1N, N-disubstituted amides that inhibit the binding of integrins to their receptorsTEXAS BIOTECHNOLOGY CORP·Filed 1999·Granted Feb 27, 2001·42 cites·17 claims
- 2280US6972296B2Carboxylic acid derivatives that inhibit the binding of integrins to their receptorsENCYSIVE PHARMACEUTICALS INC·Filed 2001·Granted Dec 6, 2005·14 cites·8 claims
- 2379US9856256B2Pyridino[1,2-A]pyrimidone analogue used as P13K inhibitorCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2015·Granted Jan 2, 2018·3 cites·16 claims
- 2479US6686382B2Sulfonamides and derivatives thereof that modulate the activity of endothelinENCYSIVE PHARMACEUTICALS INC·Filed 2000·Granted Feb 3, 2004·13 cites·87 claims
- 2578US6632829B2Sulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 2001·Granted Oct 14, 2003·9 cites·55 claims
- 2678US6420567B1N-heteroaryl aryl-substituted thienyl-furyl-and pyrrolyl-sulfonamides and derviatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1997·Granted Jul 16, 2002·32 cites·73 claims
- 2777US6432994B1Sulfonamides for treatment of endothelin-mediated disordersTEXAS BIOTECHNOLOGY CORP·Filed 1998·Granted Aug 13, 2002·30 cites·18 claims
- 2877US6030991ABenzenesulfonamides and the use thereof to modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Feb 29, 2000·47 cites·125 claims
- 2976US6265428B1Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1999·Granted Jul 24, 2001·34 cites·14 claims
- 3075US6331637B1N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1999·Granted Dec 18, 2001·26 cites·60 claims
- 3174US10787435B2ASK1 inhibitor and preparation method and use thereofFUJIAN COSUNTER PHARMACEUTICAL CO LTD·Filed 2018·Granted Sep 29, 2020·1 cites·27 claims
- 3274US10662174B2BTK inhibitorHUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC·Filed 2017·Granted May 26, 2020·1 cites·8 claims
- 3374US7288538B2Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonistsENCYSIVE PHARMACEUTICALS INC·Filed 2004·Granted Oct 30, 2007·5 cites·7 claims
- 3473US6342610B2N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Jan 29, 2002·18 cites·52 claims
- 3571US11312726B2Thienodiazepine derivatives and application thereofCSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD·Filed 2018·Granted Apr 26, 2022·1 cites·21 claims
- 3671US10513514B2Piperidine compounds as PCSK9 inhibitorsSHENZHEN SALUBRIS PHARM CO LTD·Filed 2018·Granted Dec 24, 2019·1 cites·28 claims
- 3771US7812038B2Carboxylic acid derivatives that inhibit the binding of integrins to their receptorsENCYSIVE PHARMACEUTICALS INC·Filed 2005·Granted Oct 12, 2010·1 cites·7 claims
- 3869US9879021B2Compounds as rearranged during transfection (RET) inhibitorsGLAXOSMITHKLINE IP DEV LTD·Filed 2015·Granted Jan 30, 2018·1 cites·20 claims
- 3968US7319111B2Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonistsENCYSIVE PHARMACEUTICALS INC·Filed 2004·Granted Jan 15, 2008·4 cites·4 claims
- 4066US11866433B2Diarylthiohydantoin compound as androgen receptor antagonistCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2021·Granted Jan 9, 2024·0 cites·20 claims
- 4166US6262084B1Compounds that inhibit the binding of integrins to their receptorsTEXAS BIOTECHNOLOGY CORP·Filed 1999·Granted Jul 17, 2001·18 cites·10 claims
- 4263US9868737B2Pyridino[1,2-A]pyrimidone analogue used as MTOR/P13K inhibitorCISEN PHARMACEUTICAL CO LTD·Filed 2015·Granted Jan 16, 2018·1 cites·8 claims
- 4360US6376523B1Benzenesulfonamides and the use thereof to modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1999·Granted Apr 23, 2002·19 cites·97 claims
- 4460US2025122190A1Halogen-substituted pyridazinone compound and application thereofMEDSHINE DISCOVERY INC·Filed 2022·Application pending·0 cites
- 4560US2024300975A1Dimethyl-substituted thiazololactam compound and use thereofD3 BIO WUXI CO LTD·Filed 2022·Application pending·0 cites
- 4660US2024309018A1Thiazole-lactam-spiroheterocyclic compounds and applications thereofD3 BIO WUXI CO LTD·Filed 2022·Application pending·0 cites
- 4757US2024239761A1Bicyclic phenol compounds and use thereofMEDSHINE DISCOVERY INC·Filed 2022·Application pending·0 cites
- 4856US11814382B2Crystal form as ASK1 inhibitor and preparation method and application thereofFUJIAN COSUNTER PHARMACEUTICAL CO LTD·Filed 2019·Granted Nov 14, 2023·0 cites·16 claims
- 4956US2023203057A1Five-membered heteroaromatic imidazole compound and use thereofHANGZHOU SCIWIND BIOSCIENCES CO LTD·Filed 2022·Application pending·0 cites
- 5055US2003208084A1Sulfonamides and derivatives thereof that modulate the activity of endothelinFiled 2003·Application pending·0 cites
Showing the top 50 of 82 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Chengde Wu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →